BRANDICOURT OLIVIER 4

What Happened
Olivier Brandicourt, a director of BeOne Medicines Ltd. (ONC), was granted 18,980 restricted share units (RSUs) on June 11, 2026. The award was reported on a Form 4 filed June 15, 2026. The RSUs were issued at $0.00 per share (no cash paid); total reported acquisition value = $0. This is an award/compensation grant rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Report filed (Form 4): 2026-06-15.
• Transaction type: A = Award/Grant; Shares/RSUs granted: 18,980; Price per share: $0.00; Reported value: $0.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote (from filing): RSUs become fully vested on the earlier of the first anniversary of the grant or the date of the next annual general meeting; vesting stops if the director resigns unless accelerated vesting is triggered under the company’s Independent Non‑Executive Director Compensation Policy.

Context
RSU grants are a common form of director compensation and do not by themselves indicate buying or selling sentiment. These units convert into shares only if/when they vest under the stated conditions; no immediate market sale occurred. Retail investors should view this as a compensation-related award rather than a direct vote of confidence from an open‑market purchase.